UPDATE 2-U.S. FDA lists drugs under safety probes

(Recasts first paragraph; adds additional FDA comments, details on drugs, reaction)

By Lisa Richwine

WASHINGTON, Sept 5 (Reuters) - U.S. health officials have disclosed safety probes into over 20 medicines by companies such as Eli Lilly and Co (LLY.N: Quote, Profile, Research, Stock Buzz) and Biogen Idec (BIIB.O: Quote, Profile, Research, Stock Buzz), a step required by Congress to address concerns the agency had been slow to warn of risks.

The U.S. Food and Drug Administration said on Friday that patients shouldn't overreact to the list of medicines undergoing safety probes following reports from doctors, patients and others of health problems.

Appearing on the list, agency officials said, does not mean the FDA has concluded that the drug caused the problem.

"We're telling the public really at the earliest stage what it is we're working on," said Dr. Gerald Dal Pan, director of the FDA office that monitors the safety of drugs after they reach the market.

The agency had been criticized as slow to alert patients about serious heart risks with Merck & Co's (MRK.N: Quote, Profile, Research, Stock Buzz) withdrawn arthritis pill Vioxx and reports of suicidal behavior in children taking antidepressants.

A law enacted last year required the FDA to tell the public each quarter about new safety data.

But agency officials voiced concern the preliminary information could cause patients to stop taking important drugs. "Don't stop taking your medicine," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Drugmakers also urged patients to keep taking their medicines unless a doctor tells them otherwise.

"The FDA needs to strive for communications that include the full context of the medication's benefits and risks," said Ken Johnson, a spokesman for the industry group Pharmaceutical Research and Manufacturers of America.

The list was posted at the FDA's website here .

SAFETY ISSUES

The safety issues were identified based on reports received from January through March 2008, the FDA said.

The list does not specify how many reports have been received and some problems have been previously made public.

Officials said they hoped the list would encourage more reports of any problems. Drugs on the list may be subject to future warnings or other actions from the FDA.  Continued...